Direkt zum Inhalt
Merck

SML2401

Sigma-Aldrich

Imeglimin hydrochloride

≥98% (HPLC), powder, anti-hyperglycemic compound

Synonym(e):

(6R)-1,6-dihydro-N,N,6-trimethyl-1,3,5-Triazine-2,4-diamine Hydrochloride,, (6R)-3,6-Dihydro-N2,N2,6-trimethyl-1,3,5-triazine-2,4-diamine, EMD 387008 Hydrochloride, EMD-387008 Hydrochloride, R-(4-Imino-6-methyl-1,4,5,6-tetrahydro-[1,3,5]trazin-2-yl)dimethylamine Hydrochloride

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C6H13N5 · xHCl
CAS-Nummer:
Molekulargewicht:
155.20 (free base basis)
UNSPSC-Code:
12352200
NACRES:
NA.77

Produktbezeichnung

Imeglimin hydrochloride, ≥98% (HPLC)

Qualitätsniveau

Assay

≥98% (HPLC)

Form

powder

Lagerbedingungen

desiccated

Farbe

white to beige

Löslichkeit

H2O: 2 mg/mL, clear

Lagertemp.

2-8°C

SMILES String

Cl.N1[C@@H](N=C(N=C1N(C)C)N)C

InChI

1S/C6H13N5.ClH/c1-4-8-5(7)10-6(9-4)11(2)3;/h4H,1-3H3,(H3,7,8,9,10);1H/t4-;/m1./s1

InChIKey

UXHLCYMTNMEXKZ-PGMHMLKASA-N

Verwandte Kategorien

Biochem./physiol. Wirkung

Glucose-lowering agent that appears to target mitochondrial bioenergetics
Imeglimin is a first-in-class oral glucose-lowering agent whose mechanism of action targets mitochondrial bioenergetics, resulting in increased insulin secretion in response to glucose, improved glucose uptake by skeletal muscle, and suppression of gluconeogenesis. Imeglimin has been shown to decrease reactive oxygen species overproduction and delay mPTP opening, preventing cell death during oxidative stress, protecting beta-cells. In an animal model, it has been shown to reduce metabolic syndrome-related diabetic cardiomyopathy.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

P577 Short- and long-term imeglimin treatment reduces metabolic syndrome-related diabetic cardiomyopathy
Lachaux M, Hamzaoui M, Nicol L, Fouqueray P, Bolze S, Hallakou-Bozec S, Richard V, Mulder P
European Heart Journal, 38 (2017)
D Detaille et al.
Cell death discovery, 2, 15072-15072 (2016-08-24)
Imeglimin is the first in a new class of oral glucose-lowering agents, having recently completed its phase 2b trial. As Imeglimin did show a full prevention of β-cell apoptosis, and since angiopathy represents a major complication of diabetes, we studied

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.